GREENVILLE, N.C., Sept. 7, 2021 /PRNewswire/ -- As recently presented in a plenary presentation at the 2021 American Society of Clinical Oncology (ASCO) held in June, radiopharmaceutical therapies clearly demonstrate an enormous potential in the battle against cancer. The first results of the international phase III VISION trial, establish that Lu-PSMA-617 can be safely added to the standard of care (SOC) treatment and improve radiographic progression-free survival (rPFS) as well as prolonging the overall survival compared with SOC alone in men with advanced-stage PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), supporting its adoption as a standard of care.
HMS and Isotopia strongly believe in personalized medicine, and moreover that the treatment modulation for each patient will provide more evidence of the efficacy of the existing and upcoming RPTs. Accurate quantitative molecular imaging, personalized dosimetry, treatment, and follow-up options will shift these new therapies from third/fourth line approaches to new standard of care for the benefits of cancer patients worldwide.
In this partnership, HMS and Isotopia will work together to support clinical studies to demonstrate the positive effects of personalized dosimetry and modulated RPT on patient outcomes. Supportive data will assist in establishing RPT dosimetry planning as an essential element of the therapy guidelines that are being defined by the scientific community. HMS will provide its expertise within the quantitative and dosimetry software space, while Isotopia will be bringing its radiopharmaceutical innovation and logistics.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
HMS and Isotopia are also committed to developing the dosimetry tools for Isotopia's new pipeline of therapeutic isotopes such as Tb that is currently under the last phase of development.
Frank Hebert, Vice President, Business Development at HMS shares: "We are excited to collaborate with Isotopia, a dynamic and innovative organization, directly aligned with our corporate values and vision. We are determined to improve cancer patient outcomes alongside dedicated industry partners such as Isotopia."
"We found in Hermes a partner that shares the same values as Isotopia, providing accurate, personalized and meaningful therapies. Strategic partners are key in the development of new approaches to cancer diagnosis and therapy. The global outreach and expertise that HMS has, will support our efforts to develop our new therapeutic isotope, it is most important to have a partner like HMS to provide Dosimetry tools for the medical research community," points out Karen Moshkoviz, Business development manager at Isotopia.